Share-based Payment Arrangement, Expense of Aclaris Therapeutics, Inc. from 30 Sep 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aclaris Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2014 to 30 Sep 2025.
  • Aclaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,860,000, a 4.8% decline year-over-year.
  • Aclaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,318,000, a 33% increase year-over-year.
  • Aclaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $10,856,000, a 47% decline from 2023.
  • Aclaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $20,542,000, a 37% increase from 2022.
  • Aclaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $15,039,000, a 7% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aclaris Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,318,000 $2,860,000 -$144,000 -4.8% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $12,462,000 $3,063,000 +$160,000 +5.5% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $12,302,000 $3,535,000 +$1,446,000 +69% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $10,856,000 $2,860,000 +$1,594,000 +126% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $9,262,000 $3,004,000 -$2,944,000 -49% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $12,206,000 $2,903,000 -$3,619,000 -55% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $15,825,000 $2,089,000 -$4,717,000 -69% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $20,542,000 $1,266,000 -$3,547,000 -74% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $24,089,000 $5,948,000 +$1,760,000 +42% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $22,329,000 $6,522,000 +$2,830,000 +77% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $19,499,000 $6,806,000 +$4,460,000 +190% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $15,039,000 $4,813,000 +$2,119,000 +79% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $12,920,000 $4,188,000 +$486,000 +13% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $12,434,000 $3,692,000 -$140,000 -3.7% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $12,574,000 $2,346,000 -$1,486,000 -39% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $14,060,000 $2,694,000 +$190,000 +7.6% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $13,870,000 $3,702,000 +$1,761,000 +91% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $12,109,000 $3,832,000 +$523,000 +16% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $11,586,000 $3,832,000 +$379,000 +11% 01 Jan 2021 31 Mar 2021 10-Q 03 Aug 2022 2022 Q2
Q4 2020 $11,207,000 $2,504,000 -$684,000 -21% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $11,891,000 $1,941,000 -$2,083,000 -52% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $13,974,000 $3,309,000 -$1,289,000 -28% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $15,263,000 $3,453,000 -$819,000 -19% 01 Jan 2020 31 Mar 2020 10-Q 07 May 2021 2021 Q1
Q4 2019 $16,082,000 $3,188,000 +$964,000 +43% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $15,118,000 $4,024,000 +$77,000 +2% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $15,041,000 $4,598,000 -$651,000 -12% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $15,692,000 $4,272,000 -$871,000 -17% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $16,563,000 $2,224,000 -$225,000 -9.2% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $16,788,000 $3,947,000 +$274,000 +7.5% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $16,514,000 $5,249,000 +$1,945,000 +59% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $14,569,000 $5,143,000 +$1,990,000 +63% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $12,579,000 $2,449,000 +$539,000 +28% 01 Oct 2017 31 Dec 2017 10-K 25 Feb 2020 2019 FY
Q3 2017 $12,040,000 $3,673,000 +$2,055,000 +127% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $9,985,000 $3,304,000 +$1,950,000 +144% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2018 2018 Q2
Q1 2017 $8,035,000 $3,153,000 +$1,931,000 +158% 01 Jan 2017 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $6,104,000 $1,910,000 +$1,262,000 +195% 01 Oct 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
Q3 2016 $4,842,000 $1,618,000 +$1,460,000 +924% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $3,382,000 $1,354,000 +$1,312,000 +3124% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $2,070,000 $1,222,000 +$1,179,000 +2742% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $891,000 $648,000 01 Oct 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
Q3 2015 $158,000 +$152,000 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $42,000 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $43,000 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016 2016 Q1
Q3 2014 $6,000* 01 Jul 2014 30 Sep 2014 10-Q 03 Dec 2015 2015 Q3

Aclaris Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $10,856,000 -$9,686,000 -47% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $20,542,000 +$5,503,000 +37% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $15,039,000 +$979,000 +7% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
2021 $14,060,000 +$2,853,000 +25% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $11,207,000 -$4,875,000 -30% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $16,082,000 -$481,000 -2.9% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $16,563,000 +$3,984,000 +32% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $12,579,000 +$6,475,000 +106% 01 Jan 2017 31 Dec 2017 10-K 25 Feb 2020 2019 FY
2016 $6,104,000 +$5,213,000 +585% 01 Jan 2016 31 Dec 2016 10-K 18 Mar 2019 2018 FY
2015 $891,000 +$864,000 +3200% 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2014 $27,000 01 Jan 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.